A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321

Vaccine

Volumn 24, Issue 26, 2006, Pages 5426-5433

  Fougeray, Sylvie ^a   Brignone, Chrystelle ^a   Triebel, Frédéric ^a  

^a Immutep SA   (France)

Author keywords

Dendritic cells; LAG 3; Vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; IMP 321; LAG 3 PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOPOTENTIATION; IN VITRO STUDY; INJECTION; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; GENES, MHC CLASS II; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHENOTYPE; PROTEIN BINDING; VACCINES;

EID: 33744804276     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.050     Document Type: Article

References (21)

1. Parmiani G., Castelli C., Dalerba P., Mortarini R., Rivoltini L., Marincola F.M., et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J Natl Cancer Inst 94 (2002) 805-818
2. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., and Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6 (2005) 769-776
3. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8+T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 (2005) 739-746
4. Rothenfusser S., Hornung V., Ayyoub M., Britsch S., Towarowski A., Krug A., et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+T-cell responses in vitro. Blood 103 (2004) 2162-2169
5. Badovinac V.P., Messingham K.A., Jabbari A., Haring J.S., and Harty J.T. Accelerated CD8+T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 11 (2005) 748-756
6. Prasad K.S., Andre P., He M., Bao M., Manganello J., and Phillips D.R. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signalling. Proc Natl Acad Sci USA 100 (2003) 12367-12371
7. El mir S., and Triebel F. A soluble LAG-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J Immunol 164 (2000) 5583-5589
8. Andreae S., Piras F., Burdin N., and Triebel F. Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol 168 (2002) 3874-3880
9. Buisson S., and Triebel F. MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine receptor expression by human dendritic cells. Vaccine 21 (2003) 862-868
10. Prigent P., Mir S.E., Dreano M., and Triebel F. LAG-3 induces tumor regression and antitumor immune responses in vivo. Eur J Immunol 29 (1999) 3867-3876
11. Cappello P., Triebel F., Iezzi M., Caorsi C., Quaglino E., Lollini P.L., et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res 63 (2003) 2518-2525
12. Di Carlo E., Cappello P., Sorrentino C., D'Antuono T., Pellicciotta A., Giovarelli M., et al. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. J Pathol 205 (2005) 82-91
13. Andreae S., Buisson S., and Triebel F. MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). Blood 102 (2003) 2130-2137
14. Casati C, Camisaschi C, Rini R, Arienti F, Rivoltini L, Triebel F et al. Soluble human LAG-3 molecule amplifies the in vitro generation of type-1 tumor-specific immunity. Cancer Res 2006, in press.
15. Huard B., Prigent P., Pages F., Bruniquel D., and Triebel F. T cell MHC class II molecules downregulate CD4+T cell clone response following LAG-3 binding. Eur J Immunol 26 (1996) 1180-1186
16. Triebel F. LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 24 (2003) 619-622
17. Triebel F., Hacene K., and Pichon M.-F. A soluble Lymphocyte Activation Gene-3 (sLAG-3) as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett 235 (2006) 147-153
18. Lienhardt C., Azzurri A., Amedei A., Fielding K., Sillah J., Sow O.Y., et al. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol 32 (2002) 1605-1613
19. Huard B., Gaulard P., Faure F., Hercend T., and Triebel F. Cellular expression and tissue distribution of the human LAG-3-encoded protein, a MHC class II ligand. Immunogenetics 39 (1994) 213-217
20. Baixeras E., Huard B., Miossec C., Jitsukawa S., Martin M., Hercend T., et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med 176 (1992) 327-337
21. Huard B., Prigent P., Tournier M., Bruniquel D., and Triebel F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol 25 (1995) 2718-2721